|
|
???tair.name??? >
???browser.page.title.author???
|
"siveke j"???jsp.browse.items-by-author.description???
Showing items 1-10 of 12 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2018-10 |
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
|
Mercade, TM;Bodoky, G;Siveke, J;Lee, KH;Chen, J;Mirakhur, B;Dean, A;Chen, LT;de Jong, F |
| 國家衛生研究院 |
2018-10 |
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
|
Chen, LT;Macarulla, TM;Belanger, B;Mirakhur, B;de Jong, FA;Siveke, J |
| 國家衛生研究院 |
2018-10 |
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
|
Chen, LT;Macarulla, TM;Blanc, J;Mirakhur, B;de Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, J |
| 國家衛生研究院 |
2018-06 |
Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial
|
Lakatos, G;Lee, K;Siveke, J;Blanc, J;Mercade, TM;Dean, A;Bodoky, G;Mirakhur, B;Chen, J;Wang-Gillam, A;Chen, L;de Jong, F |
| 國家衛生研究院 |
2018-06 |
The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Mercade, TM;Wang-Gillam, A;Chen, L;Blanc, J;Lee, K;Bodoky, G;Dean, A;Chen, J;Mirakhur, B;Siveke, J;de Jong, F |
| 國家衛生研究院 |
2018-06 |
Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)
|
Lee, K;Bodoky, G;Blanc, J;Siveke, J;Mercade, TM;Wang-Gillam, A;Chen, L;Mirakhur, B;Chen, J;de Jong, F |
| 國家衛生研究院 |
2018-06 |
Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)
|
Mercade, TM;Wang-Gillam, A;Chen, L;Blanc, J;Lee, K;Bodoky, G;Dean, A;Siveke, J;Mirakhur, B;Chen, J;de Jong, F |
| 國家衛生研究院 |
2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Blanc, JF;Hubner, R;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Mercade, TM;Lee, KH;Cunningham, D;Chiu, CF;Schwartsmann, G;Braiteh, F;von Hoff, D;Chen, LT;Mamlouk, K;de Jong, F;Siveke, J |
| 國家衛生研究院 |
2017-11 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) � 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Shan, YS;Mercade, TM;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, J;Belanger, B;de Jong, F;Mamlouk, K;von Hoff, D |
| 國家衛生研究院 |
2017-02 |
Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: Applicability to clinical situations
|
Wang-Gillam, A;Von Hoff, D;Siveke, J;Hubner, R;Belanger, B;Pipas, JM;Chen, LT |
Showing items 1-10 of 12 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
